About Isofol

Isofol Medical AB (publ) is a research-based biotechnology company working to improve the prognosis for patients with severe forms of cancer. The company’s drug candidate arfolitixorin aims to increase the effect of first-line standard treatment for several forms of solid tumors and is currently being studied in colorectal cancer, the world’s third most common cancer, where the medical need for better treatments is urgent. A phase Ib/II study is now being conducted with new dosing regimens that are expected to optimize the effect of the drug candidate. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.

Read more >>

Upcoming Events

  • May 21, 2025 - May 21, 2025
    Interim report January-March 2025
  • May 21, 2025 - May 22, 2025
    Annual General Meeting 2025, Gothenburg
  • July 18, 2025 - July 18, 2025
    Interim report April-June 2025

INVESTORS – latest reports and presentations

FOLLOW US

Stay updated on the latest news by
following Isofol on Linkedin.

LinkedIn logotype
Scroll to Top